Reduction of anterior uveitis flares in patients with axialspondyloarthritis on certolizumab pegol treatment: final 2-year results from themulticenter phase IV C-VIEW study

• Published in: Therapeutic advances in musculoskeletal disease Vol. 13
• Main Authors: van der Horst-Bruinsma Irene E, van Bentum Rianne E, Verbraak, Frank D, Deodhar Atul, Rath, Thomas, Hoepken Bengt, Irvin-Sellers, Oscar, Thomas, Karen, Bauer, Lars, Rudwaleit, Martin
• Format: Journal Article
• Language: English
• Published: London SAGE PUBLICATIONS, INC 01.01.2021
• Subjects: Arthritis; Biological products; Clinical trials; Immunotherapy; Inhibitor drugs; Monoclonal antibodies; Side effects; TNF inhibitors; Tumor necrosis factor-TNF; Visual impairment
• ISSN: 1759-720X; 1759-7218
• DOI: 10.1177/1759720X211003803

Introduction: Acute anterior uveitis (AAU), affecting up to 40% of patients with axialspondyloarthritis (axSpA), risks permanent visual deficits if not adequatelytreated. We report 2-year results from C-VIEW, the first study toprospectively investigate certolizumab pegol (CZP) on AAU in patients withactive axSpA at high risk of recurrent AAU. Patients and methods: C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safetyfollow-up), open-label, multicenter study. Eligible patients had activeaxSpA, human leukocyte antigen-B27 (HLA-B27) positivity and a history ofrecurrent AAU (⩾2 AAU flares in total; ⩾1 in the year priorto baseline). Patients received CZP 400 mg at weeks 0, 2 and 4, then200 mg every 2 weeks to week 96. The primary efficacyendpoint was the AAU flare event rate during 96 weeks’ CZPversus 2 years pre-baseline. Results: Of 115 enrolled patients, 89 initiated CZP (male: 63%;radiographic/non-radiographic axSpA: 85%/15%; mean disease duration:9.1 years); 83 completed week 96. There was a significant 82%reduction in AAU flare event rate during CZP versuspre-baseline [rate ratio (95% confidence interval): 0.18(0.12–0.28), p < 0.001].One hundred percent and 59.6% of patients experienced ⩾1 and⩾2 AAU flares pre-baseline, respectively, compared to 20.2% and11.2% during treatment. Age, sex and axSpA population subgroup analyses wereconsistent with the primary analysis. There were substantial improvements inaxSpA disease activity with no new safety signal identified. Conclusion: CZP treatment significantly reduced AAU flare event rate in patients withaxSpA and a history of AAU, indicating CZP is a suitable treatment optionfor patients at risk of recurrent AAU. Trial Registration ClinicalTrials.gov: NCT03020992, URL: https://clinicaltrials.gov/ct2/show/NCT03020992 SAGE-Journals-Accessible-Video-Player 10.1177/1759720X211003803.M1 sj-vid-1-tab-10.1177_1759720X211003803